Literature DB >> 24379294

Oral intoxication of mice with Shiga toxin type 2a (Stx2a) and protection by anti-Stx2a monoclonal antibody 11E10.

L M Russo1, A R Melton-Celsa, M A Smith, M J Smith, A D O'Brien.   

Abstract

Shiga toxin (Stx)-producing Escherichia coli (STEC) strains cause food-borne outbreaks of hemorrhagic colitis and, less commonly, a serious kidney-damaging sequela called the hemolytic uremic syndrome (HUS). Stx, the primary virulence factor expressed by STEC, is an AB5 toxin with two antigenically distinct forms, Stx1a and Stx2a. Although both toxins have similar biological activities, Stx2a is more frequently produced by STEC strains that cause HUS than is Stx1a. Here we asked whether Stx1a and Stx2a act differently when delivered orally by gavage. We found that Stx2a had a 50% lethal dose (LD50) of 2.9 μg, but no morbidity occurred after oral intoxication with up to 157 μg of Stx1a. We also compared several biochemical and histological parameters in mice intoxicated orally versus intraperitoneally with Stx2a. We discovered that both intoxication routes caused similar increases in serum creatinine and blood urea nitrogen, indicative of kidney damage, as well as electrolyte imbalances and weight loss in the animals. Furthermore, kidney sections from Stx2a-intoxicated mice revealed multifocal, acute tubular necrosis (ATN). Of particular note, we detected Stx2a in kidney sections from orally intoxicated mice in the same region as the epithelial cell type in which ATN was detected. Lastly, we showed reduced renal damage, as determined by renal biomarkers and histopathology, and full protection of orally intoxicated mice with monoclonal antibody (MAb) 11E10 directed against the toxin A subunit; conversely, an irrelevant MAb had no therapeutic effect. Orally intoxicated mice could be rescued by MAb 11E10 6 h but not 24 h after Stx2a delivery.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24379294      PMCID: PMC3957995          DOI: 10.1128/IAI.01264-13

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  50 in total

1.  Elastase in intestinal mucus enhances the cytotoxicity of Shiga toxin type 2d.

Authors:  J F Kokai-Kun; A R Melton-Celsa; A D O'Brien
Journal:  J Biol Chem       Date:  2000-02-04       Impact factor: 5.157

2.  Neutralizing antibodies to Shiga toxin type 2 (Stx2) reduce colonization of mice by Stx2-expressing Escherichia coli O157:H7.

Authors:  Krystle L Mohawk; Angela R Melton-Celsa; Cory M Robinson; Alison D O'Brien
Journal:  Vaccine       Date:  2010-05-14       Impact factor: 3.641

3.  Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins.

Authors:  Y Endo; K Tsurugi; T Yutsudo; Y Takeda; T Ogasawara; K Igarashi
Journal:  Eur J Biochem       Date:  1988-01-15

4.  Rescue from lethal Shiga toxin 2-induced renal failure with a cell-permeable peptide.

Authors:  Deborah J Stearns-Kurosawa; Valta Collins; Scott Freeman; Diann Debord; Kiyotaka Nishikawa; Sun-Young Oh; Caitlin S Leibowitz; Shinichiro Kurosawa
Journal:  Pediatr Nephrol       Date:  2011-05-21       Impact factor: 3.714

5.  Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga-like toxin type II.

Authors:  E A Wadolkowski; L M Sung; J A Burris; J E Samuel; A D O'Brien
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

Review 6.  Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.

Authors:  Phillip I Tarr; Carrie A Gordon; Wayne L Chandler
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

7.  Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans.

Authors:  P Boerlin; S A McEwen; F Boerlin-Petzold; J B Wilson; R P Johnson; C L Gyles
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

8.  Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli.

Authors:  N A Strockbine; L R Marques; R K Holmes; A D O'Brien
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

9.  Virulence of enterohemorrhagic Escherichia coli O91:H21 clinical isolates in an orally infected mouse model.

Authors:  S W Lindgren; A R Melton; A D O'Brien
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

10.  Attribution of foodborne illnesses, hospitalizations, and deaths to food commodities by using outbreak data, United States, 1998-2008.

Authors:  John A Painter; Robert M Hoekstra; Tracy Ayers; Robert V Tauxe; Christopher R Braden; Frederick J Angulo; Patricia M Griffin
Journal:  Emerg Infect Dis       Date:  2013-03       Impact factor: 6.883

View more
  18 in total

1.  Review of Restricted Experiment Requests, Division of Select Agents and Toxins, Centers for Disease Control and Prevention, 2006-2013.

Authors:  Jacinta Smith; Denise Gangadharan; Robbin Weyant
Journal:  Health Secur       Date:  2015-09-08

2.  Shiga Toxin Type 1a (Stx1a) Reduces the Toxicity of the More Potent Stx2a In Vivo and In Vitro.

Authors:  Courtney D Petro; Eszter Trojnar; James Sinclair; Zhi-Mei Liu; Mark Smith; Alison D O'Brien; Angela Melton-Celsa
Journal:  Infect Immun       Date:  2019-03-25       Impact factor: 3.441

3.  The A1 Subunit of Shiga Toxin 2 Has Higher Affinity for Ribosomes and Higher Catalytic Activity than the A1 Subunit of Shiga Toxin 1.

Authors:  Debaleena Basu; Xiao-Ping Li; Jennifer N Kahn; Kerrie L May; Peter C Kahn; Nilgun E Tumer
Journal:  Infect Immun       Date:  2015-10-19       Impact factor: 3.441

4.  Bimodal Response to Shiga Toxin 2 Subtypes Results from Relatively Weak Binding to the Target Cell.

Authors:  Patrick Cherubin; Dennis Fidler; Beatriz Quiñones; Ken Teter
Journal:  Infect Immun       Date:  2019-11-18       Impact factor: 3.441

Review 5.  Shiga Toxin (Stx) Classification, Structure, and Function.

Authors:  Angela R Melton-Celsa
Journal:  Microbiol Spectr       Date:  2014-08

6.  An Environmental Shiga Toxin-Producing Escherichia coli O145 Clonal Population Exhibits High-Level Phenotypic Variation That Includes Virulence Traits.

Authors:  Michelle Qiu Carter; Beatriz Quinones; Xiaohua He; Wayne Zhong; Jacqueline W Louie; Bertram G Lee; Jaszemyn C Yambao; Robert E Mandrell; Michael B Cooley
Journal:  Appl Environ Microbiol       Date:  2015-12-04       Impact factor: 4.792

7.  Hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli infection in Argentina: update of serotypes and genotypes and their relationship with severity of the disease.

Authors:  Laura F Alconcher; Alejandro Balestracci; Paula A Coccia; Angela Del C Suarez; Flavia B Ramírez; Marta L Monteverde; María Graciela Perez Y Gutiérrez; Paula M Carlopio; Illiana Principi; Patricia Estrella; Susana Micelli; Daniela C Leroy; Nahir E Quijada; Claudia Seminara; Marta I Giordano; Susana B Hidalgo Solís; Mariana Saurit; Alejandra Caminitti; Andrea Arias; Miguel Liern; Marta Rivas
Journal:  Pediatr Nephrol       Date:  2021-02-18       Impact factor: 3.714

8.  Comparisons of native Shiga toxins (Stxs) type 1 and 2 with chimeric toxins indicate that the source of the binding subunit dictates degree of toxicity.

Authors:  Lisa M Russo; Angela R Melton-Celsa; Michael J Smith; Alison D O'Brien
Journal:  PLoS One       Date:  2014-03-26       Impact factor: 3.240

9.  Eliglustat prevents Shiga toxin 2 cytotoxic effects in human renal tubular epithelial cells.

Authors:  Daiana S Sánchez; Lilian K Fischer Sigel; Alejandro Balestracci; Cristina Ibarra; María M Amaral; Claudia Silberstein
Journal:  Pediatr Res       Date:  2021-06-21       Impact factor: 3.756

10.  Shiga Toxin (Stx) Type 1a Reduces the Oral Toxicity of Stx Type 2a.

Authors:  Lisa M Russo; Angela R Melton-Celsa; Alison D O'Brien
Journal:  J Infect Dis       Date:  2016-01-06       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.